Aptevo Therapeutics (APVO) to Release Quarterly Earnings on Friday

Aptevo Therapeutics (NASDAQ:APVO) is expected to post its results before the market opens on Friday, February 13th. Analysts expect Aptevo Therapeutics to post earnings of ($8.09) per share for the quarter.

Aptevo Therapeutics (NASDAQ:APVO) last released its quarterly earnings results on Thursday, November 6th. The biotechnology company reported ($40.14) earnings per share for the quarter, missing the consensus estimate of ($37.62) by ($2.52). On average, analysts expect Aptevo Therapeutics to post $-16 EPS for the current fiscal year and $-14 EPS for the next fiscal year.

Aptevo Therapeutics Stock Down 6.2%

Aptevo Therapeutics stock opened at $6.01 on Friday. The business has a 50-day simple moving average of $13.64 and a two-hundred day simple moving average of $25.56. The company has a market cap of $6.00 million, a P/E ratio of 0.00 and a beta of 1.49. Aptevo Therapeutics has a 52-week low of $5.94 and a 52-week high of $1,551.60.

Hedge Funds Weigh In On Aptevo Therapeutics

An institutional investor recently bought a new position in Aptevo Therapeutics stock. Virtu Financial LLC bought a new position in Aptevo Therapeutics Inc. (NASDAQ:APVO) during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 38,282 shares of the biotechnology company’s stock, valued at approximately $56,000. Virtu Financial LLC owned about 1.16% of Aptevo Therapeutics as of its most recent SEC filing. 8.06% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts have commented on the company. Wall Street Zen cut Aptevo Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, January 17th. Weiss Ratings reiterated a “sell (e)” rating on shares of Aptevo Therapeutics in a research report on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Aptevo Therapeutics presently has an average rating of “Hold”.

Aptevo Therapeutics Company Profile

Aptevo Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Seattle, Washington, focused on the discovery and development of novel immunotherapies for oncology and autoimmune diseases. Founded in 2012 as a spin-off from Emergent BioSolutions, the company builds on expertise in protein engineering and translational research to create targeted biologics that engage the body’s immune system.

The company’s core technologies include the ADAPTIR platform, which enables the design of bispecific and multispecific protein scaffolds with customizable binding domains, and the KNOCKOUT platform, which incorporates non-natural amino acids to enhance therapeutic properties such as stability and half-life.